Targeted Knockdown of Insulin-Like Growth Factor Binding Protein-2 Disrupts Cardiovascular Development in Zebrafish Embryos

Antony W. Wood, Peter J. Schlueter and Cunming Duan

Department of Molecular, Cellular and Developmental Biology, University of Michigan, Ann Arbor, Michigan 48109

Address all correspondence and requests for reprints to: Cunming Duan, Department of Molecular, Cellular and Developmental Biology, University of Michigan, 830 North University Avenue, Ann Arbor, Michigan 48109. E-mail: cduan{at}umich.edu.


    ABSTRACT
 TOP
 ABSTRACT
 INTRODUCTION
 RESULTS
 DISCUSSION
 MATERIALS AND METHODS
 REFERENCES
 
IGF binding protein-2 (IGFBP-2) is an evolutionarily conserved protein that binds IGFs and modulates their biological activities. Although the actions of IGFBP-2 have been well studied in vitro, we have a poor understanding of its in vivo functions, particularly during early development. Using the transparent zebrafish embryo as a model, we show that IGFBP-2 mRNA is expressed in lens epithelium and cranial boundary regions during early embryonic development and becomes localized to the liver by the completion of embryogenesis. Targeted knock-down of IGFBP-2 by antisense morpholino-modified oligonucleotides resulted in delayed development, reduced body growth, reduced IGF-I mRNA levels, and disruptions to cardiovascular development, including reduced blood cell number, reduced blood circulation, cardiac dysfunction, and brain ventricle edema. Detailed examination of vascular tissues, using a stable transgenic line of zebrafish expressing green fluorescent protein in vascular endothelial cells, revealed specific angiogenic (vessel sprouting) defects in IGFBP-2 knockdown embryos, with effects being localized in regions associated with IGFBP-2 mRNA expression. These findings suggest that IGFBP-2 is required for general embryonic development and growth and plays a local role in regulating vascular development in a model vertebrate organism.


    INTRODUCTION
 TOP
 ABSTRACT
 INTRODUCTION
 RESULTS
 DISCUSSION
 MATERIALS AND METHODS
 REFERENCES
 
THE IGF BINDING PROTEINS (IGFBPs) constitute a family of evolutionarily conserved proteins that are thought to play a critical role in modulating the cellular responses to IGF signaling (1, 2, 3, 4). IGFBPs are secreted proteins found in greatest abundance in the serum, where they are believed to serve an endocrine function by prolonging the half-life of circulating IGFs (5). IGFBPs are also expressed in many peripheral tissues during fetal and postnatal development, although their specific functions in this context are much less clear (3).

Among the six known IGFBPs in mammals, IGFBP-2 is one of the most abundantly expressed, particularly during fetal development (6, 7). Whereas in vitro studies suggest that IGFBP-2 is primarily inhibitory to IGF actions (1, 2), a clear understanding of its functions in vivo remains elusive. All known vertebrate homologs of IGFBP-2 contain a putative heparin-binding motif (PKKXRP), and mammalian IGFBP-2 proteins have been shown to interact directly with extracellular matrix proteins (1, 2). These properties suggest that IGFBP-2 may function in a paracrine fashion to coordinate the precise delivery of IGFs to the surface of cells expressing IGF receptors (3, 4).

Quite surprisingly, homologous deletion of the IGFBP-2 gene in mice resulted in few phenotypic effects: knockout progeny were both viable and fertile and had prenatal and postnatal body weights indistinguishable from those of their wild-type litter mates (8). Tissue-specific effects of IGFBP-2 gene deletion (reduced spleen, enlarged liver) were subsequently observed, but only in adult mice (8), leaving in question the functional roles of IGFBP-2 during fetal development.

Two explanations have been offered to account for the lack of developmental and growth defects in IGFBP-2 knockout mice. First, compensatory adjustments in the expression of other IGFBPs may have minimized deleterious effects of gene deletion; for example, serum levels of IGFBP-1, -3, and -4 were significantly increased in IGFBP-2 knockout mice (8). Second, factors delivered through the placental circulation may have compensated for the absence of IGFBP-2. These issues exemplify some of the difficulties inherent to the study of early development in placental vertebrates.

During the last decade, the zebrafish has emerged as an excellent alternative model for the study of early vertebrate development (9). Embryos of this species develop externally, providing the opportunity to study gene and protein function in the absence of maternal compensation. The optical clarity of zebrafish embryos also permits real-time visualization of tissue and organ formation, a property that has been enhanced by the development of transgenic lines expressing reporter genes (e.g. green fluorescent protein, GFP) under the control of tissue-specific promoters. This species is also amenable to genetic loss-of-function approaches, including targeted gene knockdown by morpholino-modified antisense oligonucleotides (MOs), which specifically suppress the translation of target gene mRNAs (10).

The IGF signaling system (ligands, receptors, and binding proteins) is highly conserved among vertebrates, including zebrafish and other teleosts (11, 12, 13, 14, 15). We previously reported the zebrafish IGFBP-2 gene to encode a protein that has high affinity for both IGF-I and IGF-II (but not insulin) and that inhibits IGF-induced cell growth in vitro (14). The objectives of the present study were to examine the expression pattern of IGFBP-2 mRNA during zebrafish embryonic development and to determine the physiological requirements for IGFBP-2 during early development, using a loss-of-function approach.


    RESULTS
 TOP
 ABSTRACT
 INTRODUCTION
 RESULTS
 DISCUSSION
 MATERIALS AND METHODS
 REFERENCES
 
IGFBP-2 mRNA Exhibits Tissue- and Developmental Stage-Specific Expression in Zebrafish Embryos
RT-PCR analyses using total RNA from whole-embryo homogenates revealed that IGFBP-2 mRNA is expressed in zebrafish embryos throughout the pregastrula period [0–10 hpf (hours post fertilization); Fig. 1AGo], confirming that IGFBP-2 mRNA is provided as a maternal transcript and is expressed by the zygotic genome throughout the cleavage and gastrulation stages of embryonic development.



View larger version (62K):
[in this window]
[in a new window]
 
Fig. 1. Developmental Expression of IGFBP-2 mRNA

A, RT-PCR amplification of partial cDNA for IGFBP-2. Numbers above lanes refer to stage of embryos (hpf); numbers to left indicate DNA size (bp). MW, DNA molecular weight standard; NC, negative control (no cDNA template for PCR). B, Whole-mount in situ hybridization for IGFBP-2 in zebrafish embryos. Lateral-view images are oriented with anterior to left and dorsal to the top. Arrows indicate positive signal for IGFBP-2 mRNA. Numbers in panels indicate age of embryos (hpf); 30h-inset, cryosectioned eye of 30 hpf embryo. 56h-a, Lateral view, 56 h-b, dorsal view of anterior region in a 56-hpf embryo. Note the progression toward a liver-specific expression pattern at the completion of embryogenesis (96h).

 
Using whole-mount in situ hybridization, we were unable to detect IGFBP-2 mRNA before 18 hpf, at which time IGFBP-2 mRNA became detectable in the developing lens (Fig. 1BGo, 18h). By 30 hpf, a strong hybridization signal was detected in the peripheral lens (Fig. 1BGo, 30h): examination of cryosectioned embryos revealed localized expression of IGFBP-2 mRNA in cuboidal epithelial cells on the lateral surface of the lens (Fig. 1BGo, 30h; inset).

From about 32 hpf onwards, IGFBP-2 mRNA expression became detectable in cranial boundary regions. The location of IGFBP-2 mRNA expression resembled known vascular pathways (16), although double-labeling experiments (using transgenic zebrafish expressing GFP in vascular endothelial cells) suggested that IGFBP-2 mRNA-expressing cells were adjacent to vascular endothelial cells (data not shown). At the present time, the precise identity of the cells expressing IGFBP-2 remains unknown. Expression in these regions persisted throughout the hatching period (Fig. 1BGo, 56h-a and -b) until approximately 80 hpf; by approximately 60 hpf, however, expression also became detectable in the newly formed liver (Fig. 1BGo, 72h). By 96 hpf and beyond, IGFBP-2 mRNA expression was detected most abundantly in the liver (Fig. 1Go, 96h).

Antisense MOs Specifically and Efficiently Knock Down IGFBP-2 in Vivo
Microinjection of plasmid DNA (50–100 pg/embryo) encoding an IGFBP-2-GFP fusion protein (BP2:GFP) into zebrafish embryos yielded pronounced mosaic GFP expression, clearly visible at 24 hpf by fluorescence microscopy (Fig. 2AGo). Coinjection of BP2:GFP plasmid DNA (50 pg) with 2–3 ng of either antisense IGFBP-2 targeting MO (MO1, MO2; Table 1Go) completely abolished BP2:GFP expression (Fig. 2Go, B and C), whereas coinjection with a control MO (CTRL; Table 1Go) failed to abolish GFP expression. Likewise, coinjection of either MO1 or MO2 with an expression plasmid encoding zebrafish IGFBP-3:GFP (Li, Y., and C. Duan, unpublished data) produced embryos with pronounced mosaic GFP expression (Fig. 2CGo). Collectively, these data confirm that antisense MOs targeted against IGFBP-2 specifically and efficiently suppress the translation of IGFBP-2 mRNA into functional protein but do not suppress the translation of a closely related nontarget gene. Whereas a preferable method would have been to directly measure the quantities of endogenous IGFBP-2 protein, we were unable to achieve this due to the lack of cross-reactivity between a commercially available (bovine) anti-IGFBP-2 antibody and zebrafish IGFBP-2. Similarly, ligand blotting approaches were insufficiently sensitive to detect IGFBP-2 protein levels during early stages of embryonic development in zebrafish.



View larger version (39K):
[in this window]
[in a new window]
 
Fig. 2. Specific and Efficient Knockdown of IGFBP-2:GFP by MOs

A, Fluorescence microscopy image of zebrafish embryos injected with plasmid DNA encoding a BP2:GFP fusion protein. GFP expression (green) is detectable in a mosaic pattern throughout injected embryos; B, fluorescence microscopy image of zebrafish embryos coinjected with BP-2:GFP plasmid and antisense MO targeted against IGFBP-2 (MO1 or MO2). Note the absence of detectable GFP expression in all embryos; C, summary data of coinjection experiments. Y-axis values indicate proportion of embryos exhibiting GFP expression after coinjection of specified plasmid DNA various MOs.

 

View this table:
[in this window]
[in a new window]
 
Table 1. Morpholino Oligonucleotides Used in this Study

 
Knockdown of IGFBP-2 Results in Developmental Delay and Growth Retardation
Control-injected embryos were morphologically indistinguishable from wild-type siblings at 24 hpf (Fig. 3Go, A and B), whereas embryos injected with MO1 or MO2 (morphant embryos) exhibited delayed embryonic development (Fig. 3Go, C and D). Somite number (Fig. 3EGo) was used as a quantitative measure of developmental rate during the segmentation period (20). At 24 hpf, control-injected embryos had 29.3 ± 0.17 somites (n = 26) (30 somites at 24 hpf in wild-type embryos); embryos injected with 2.5 ng of MO1 had an average of 29.8 ± 0.45 somites (P = 0.09; n = 13), whereas embryos injected with 5 ng of MO1 had an average of 25.7 ± 0.34 somites (P < 0.0001; n =26). Embryos injected with 5 ng of MO1 were therefore developmentally equivalent to wild-type and control-injected embryos at 22 hpf (20). As shown in Fig. 3FGo, injection of MO1 also significantly reduced the mean length (ear-tail) from 2.39 ± 0.04 mm (n =19) of the control embryos to 2.69 ± 0.03 mm (n = 14) of the morphant embryos (P < 0.0001).



View larger version (32K):
[in this window]
[in a new window]
 
Fig. 3. Morphology of Wild-Type (A), Control MO-Injected (B), and IGFBP-2 Targeting Antisense MO (MO1)-Injected (C, 2.5 ng/Embryo; D, 5 ng/Embryo) Embryos at 25 hpf

Note visibly delayed development of MO1-injected embryos. E, Mean umber of somite pairs in 24 hpf zebrafish embryos after injection with control (CTRL) or MO1. Quantity of injected MO/embryo indicated at bottom. F, Mean ear-tail length (millimeters) of zebrafish embryos at 56 hpf, after injection with either control (CTRL) or MO1. *, Significant difference from mean value of control MO-injected embryos (t test, P < 0.0001).

 
Knockdown of IGFBP-2 Reduces IGF-I mRNA Levels
Disruptions to the expression of one component of the IGF system has previously been shown to influence the expression of other IGF gene family members (10). To determine whether MO-mediated knockdown of IGFBP-2 altered the expression of other IGF system genes, we measured mRNA expression levels of IGFBP-2, IGFBP-5, IGF-I, and IGF-II in control- injected and morphant embryos 48 h after microinjection, using semiquantitative RT-PCR. Expression levels were normalized to expression levels of ornithine decarboxylase (odc). The relative mRNA levels of IGF-II, IGFBP-2, and IGFBP-5 mRNA in morphant embryos were not significantly different between control-injected and morphant embryos, indicating that knockdown of IGFBP-2 did not result in detectable changes to the mRNA content of these transcripts. However, IGF-I mRNA levels in morphant embryos (Fig. 4Go) were significantly reduced compared with control-injected embryos (n = 5; P = 0.0016).



View larger version (42K):
[in this window]
[in a new window]
 
Fig. 4. Relative Changes in mRNA Levels of IGFs and Related Genes after Knockdown of IGFBP-2

A, Representative gel images of RT-PCR products from control MO-injected (lanes 1, 2) or IGFBP-2 targeting antisense MO1-injected (lanes 3 and 4) zebrafish embryos (48 hpf). B, Relative levels of mRNA of the indicated genes. The relative expression levels in the IGFBP-2 morphant embryos in comparison to those of the control MO-injected (100%) are shown. Values are means ± SEM of at least three separate experiments. *, Statistically significant reduction in mRNA expression levels (P < 0.01) compared with the control MO-injected group. BP-2, IGFBP-2; BP-5, IGFBP-5.

 
Knockdown of IGFBP-2 Disrupts Cardiovascular Development
Defects in cardiovascular development and/or integrity became evident in the IGFBP-2 knockdown embryos after 25 hpf, coincident with the onset of blood circulation. At this stage in wild-type and control-injected embryos, circulating blood cells (primary erythrocytes) become clearly visible in the primary axial vessels of the trunk (e.g. dorsal aorta), in the common cardinal veins traversing the yolk sac toward the heart, and throughout the anterior (cranial) regions of the embryo (supplemental Fig. 1Go, published on The Endocrine Society’s Journals Online web site at http://mend.endojournals.org). Embryos injected with MO1 or MO2 (2.5 ng/embryo) exhibited a visible reduction in the density of circulating blood cells (supplemental Fig. 2Go). The reduction in circulating blood cells in morphant embryos was confirmed by reduced o-dianisidine staining for hemoglobin, when compared with equivalent stage (48 hpf) control-injected embryos (Fig. 5Go, A and B). In a representative experiment, severely affected morphant embryos (11/18, 61%) exhibited a complete absence of o-dianisidine staining, whereas more mildly affected morphant embryos (5/18, 27%) exhibited visibly reduced o-dianisidine staining (Fig. 5Go, A and B). Beyond 30 hpf, the development of cerebral and/or pericardial edema became evident in a majority (91%) of morphant embryos (Fig. 5Go, C and D), whereas no equivalent phenotype was observed in control-injected embryos.



View larger version (55K):
[in this window]
[in a new window]
 
Fig. 5. Knockdown of IGFBP-2 Disrupts Cardiovascular Development

A and B, Ventral (yolk-sac) view of 48 hpf zebrafish embryos stained for hemoglobin with o-dianisidine. Dark staining (arrows) indicates hemoglobinated blood cells (traversing cardinal veins of yolk sac). A, Control MO-injected embryos; B, IGFBP-2 targeting antisense MO1-injected (morphant) embryos. Note the reduced hemoglobin staining in morphant embryos. C and D, Lateral view of cranial region of zebrafish embryos at 48 hpf: C, control MO-injected embryos; D, IGFBP-2 targeting antisense MO1-injected (morphant) embryos. Note the development of edema (arrow) in the hindbrain (4th ventricle) of morphant embryos. E, Mean heart rates of control MO-injected (solid bars) and morphant (open bars) zebrafish embryos at 28 hpf and 32 hpf. *, Significant difference from equivalent stage control-injected embryos (P < 0.05).

 
We also noted an apparent reduction in the heart rates of morphant embryos when compared with control-injected embryos. The mean heart rate of control-injected embryos at 28 hpf was 95.2 ± 2.3 beats/min (n = 20); the mean heart rate of morphant embryos at 28 hpf (76.1 ± 2.7 beats/min, n = 20) was significantly lower (P < 0.0001) than control-injected embryos at the same time point (Fig. 5EGo). Because the zebrafish heart rate gradually increases during the first few days of embryonic development (21), we sought to determine whether the lower heart rate in morphant embryos could be attributed to delayed development. Heart rates were thus measured again on the same individuals at 32 hpf: the mean heart rate of control-injected embryos at 32 hpf had increased by 15.2% to 110 ± 2.7 beats/min (n = 20); by contrast, the mean heart rate of morphant embryos at 32 hpf had decreased by 13.7% (65.7 ± 2.5 beats/min; n = 20) from the mean value at 28 hpf, indicating progressive cardiac dysfunction in IGFBP-2 morphant embryos.

Knockdown of IGFBP-2 Affects Hematopoietic Transcription Factor Expression Patterns
To determine whether the reductions in blood cell density in morphant embryos were the result of changes in the blood cell differentiation, we performed in situ hybridizations to determine the expression patterns of selected hematopoietic transcription factors. At 18 hpf, we detected robust expression of gata1, a marker for erythroid differentiation, in the intermediate cell mass region of both control-injected (Fig. 6AGo; n = 8) and morphant (Fig. 6BGo; n = 8) embryos, in patterns identical with that seen in wild-type embryos (22). At 25 hpf, control-injected embryos continued to exhibit strong expression of gata1 (Fig. 6CGo), from the intermediate cell mass extending anteriorly along the central axis, whereas gata1 expression in morphant embryos was greatly reduced or abolished at 25 hpf (Fig. 6DGo). Similar results were observed with the lymphoid marker stem cell leukemia (scl): expression was robust in control-injected embryos at 25 hpf (Fig. 6EGo) but was reduced or abolished in equivalent-stage morphant embryos (Fig. 6FGo). These effects were specific to blood markers because expression of selected neuronal transcription factors (e.g. Pax2.1; Fig. 6Go, G and H) was not affected in 25 hpf morphant embryos.



View larger version (39K):
[in this window]
[in a new window]
 
Fig. 6. In Situ Hybridization Analysis Using Markers for Hematopoietic and Neuronal Differentiation, in Control MO-Injected (Upper Panel) and IGFBP-2 Targeting Antisense MO-Injected (Morphant, Lower Panel) Embryos

A and B, gata1 in 18 hpf embryos; C and D, gata1 in 25 hpf embryos; E and F, scl in 25 hpf embryos; (G and H) Pax2.1 in 25 hpf embryos. Arrows indicate sites of detectable mRNA hybridization signal; gata1 and scl mRNA is reduced or absent in morphant embryos at 25 hpf (D and F), but no effects of MO knockdown are observed with Pax2.1 in equivalent stage embryos.

 
Knockdown of IGFBP-2 Disrupts Vascular Development in Zebrafish Embryos
The disruptions to general circulation in morphant embryos led us to hypothesize alternately that knockdown of IGFBP-2 compromised the development or integrity of vascular tissues. To test this hypothesis, we knocked down IGFBP-2 expression in flk1:GFP zebrafish embryos (20). flk1:GFP zebrafish possess stable integration of a reporter construct (GFP) fused to the promoter region of vascular endothelial growth factor receptor-2 (flk1). flk1:GFP zebrafish exhibit green fluorescence in vascular endothelial cells, permitting visualization of the developing vascular system in vivo (20). We detected no gross defects to primary vasculogenesis in IGFBP-2 morphant embryos (Fig. 7Go, A and B), but examination of secondary vascular structures revealed vascular patterning defects in regions associated with IGFBP-2 mRNA expression. Specifically, vessels medial to the lens were clearly distinguishable in control-injected embryos at 30 hpf (Fig. 6CGo), whereas corresponding vessels were generally absent or disorganized in equivalent-stage morphant embryos (Fig. 6DGo). Similarly, angiogenic sprouting of secondary vessels between the primordial hindbrain channel (PHBC) and the basilar artery was clearly visible in control-injected embryos by 36 hpf (Fig. 6EGo); by contrast, there was a visible reduction in secondary vessel development in equivalent-stage IGFBP-2 morphant embryos (Fig. 6FGo).



View larger version (20K):
[in this window]
[in a new window]
 
Fig. 7. Fluorescent Microscopy Images of Whole Body (A and B), Ocular (C and D), and Cranial (E and F) Vascular Structures in flk1:GFP Transgenic Embryos Injected with CTRL (A, C, and E) or IGFBP-2 Targeting Antisense MO (MO-1) (B, D, and F)

A and B, Primary and secondary vessels in the trunk develop normally in both control and morphant embryos; C, secondary vessels (arrows) adjacent to the lens in control-injected embryos; D, corresponding vessels are absent in IGFBP-2 morphant embryo. E, Secondary vessel sprouting (between arrows) is visible from the PHBC in representative control-injected embryo; F, vessel sprouting is reduced in representative IGFBP-2 morphant embryo. Scale bars, 25 µm in C and D; 100 µm in E and F. G, Mean number of visible secondary vessels sprouting from the PHBC in wild-type (WT), control-injected, and IGFBP-2 morphant embryos at 48 hpf. Values are means ± SEM; *, significant difference from control-injected embryos (P < 0.05).

 
To quantify these defects, we counted the number of visible secondary vessels sprouting from the primordial hindbrain channel of control-injected and morphant embryos at 48 hpf (Fig. 6GGo). The mean number of secondary vessels in control-injected embryos (5.1 ± 0.3; n =12) did not differ significantly from the mean number of secondary vessels in wild-type embryos (5.0 ± 0.4; n = 8; P > 0.05); however, the mean number of secondary vessels sprouting from the PHBC in morphant embryos (1.8 ± 0.3; n =18) was significantly lower than the mean values of both control-injected and wild-type embryos (P < 0.0001).


    DISCUSSION
 TOP
 ABSTRACT
 INTRODUCTION
 RESULTS
 DISCUSSION
 MATERIALS AND METHODS
 REFERENCES
 
In this study, we have shown that IGFBP-2 mRNA exhibits spatially and temporally distinct patterns of expression during zebrafish embryogenesis, suggesting possible paracrine and/or autocrine functions for this IGFBP during early development. Using a loss-of-function approach, we have furthermore provided in vivo evidence that IGFBP-2 is not only required for global embryonic development and growth but may also play a specific functional role in cardiovascular development. Specifically, targeted knockdown of IGFBP-2 yielded embryos with reduced blood cell densities, disruptions to blood circulation, cardiac dysfunction, and pronounced cerebral edema. These phenotypic defects are consistent with disruptions to vascular function and/or integrity, as previously described in other teleost embryos (20, 21, 22, 23, 24).

The detection of IGFBP-2 mRNA in gastrula embryos indicates that IGFBP-2 mRNA is initially endowed as a maternal transcript. mRNA transcripts encoding IGF-I, IGF-II, and type-1 IGF receptors were previously reported in unfertilized zebrafish eggs (12), suggesting that the IGF signaling system as a whole is present and may be functional during the initial stages of embryonic development. These findings are of interest, in light of considerable debate regarding the functional requirements for IGF signaling in embryonic development in mammals (8, 25). Later in the segmentation period (10–24 hpf), IGFBP-2 begins to exhibit spatially distinct patterns of expression, although these differ somewhat from the patterns reported in other vertebrate embryos. For example in the chick embryo, IGFBP-2 mRNA expression was initially localized to the primitive streak region and was later expressed in anterior lateral plate mesoderm and in regions adjacent to developing somites (26). In the ovine fetus, IGFBP-2 mRNA was initially widely expressed, before becoming restricted to liver, kidney and choroid plexus during later fetal development (27). Interestingly, the lens vesicle consistently exhibited detectable IGFBP-2 mRNA expression in the embryonic mouse (embryonic d 9.5-13.5), which is consistent with our observations in early (18–32 hpf) zebrafish embryos. However, the distribution of detectable IGFBP-2 expression in the fetal mouse increased throughout development (28), whereas in zebrafish it retained high tissue specificity, becoming specifically localized to brain boundary regions in close proximity to vascular pathways. Finally, near the completion of embryonic development, the zebrafish liver becomes the primary source of IGFBP-2, which is consistent with an endocrine role for IGFBP-2 during juvenile and adult development (13, 14, 27, 29).

Using MOs, we next examined the phenotypic consequences of targeted IGFBP-2 gene suppression. Knockdown of IGFBP-2 in zebrafish embryos resulted in delayed development, as indicated by the reduced rate of somitogenesis during the segmentation stage, and reduced linear body growth during later stages. These data suggest that IGFBP-2 serves a growth-promoting function in early development, which is seemingly contradictory to the conventional view of IGFBP-2 function. Data from a large number of studies suggest that IGFBP-2 functions primarily to inhibit IGF-mediated cell growth, presumably by sequestering IGFs and preventing their interaction with IGF-I receptors (2, 4). However, most of these data are derived from in vitro model systems, which cannot reproduce the complexity of molecular interactions in vivo. These in vitro data are also inconsistent with the high levels of IGFBP-2 observed during fetal development, a period of distinctly rapid somatic growth and differentiation. Importantly, there are precedents for our data suggesting that IGFBP-2 plays a growth-promoting function in vivo: for example, targeted knockout of IGFBP-4, which has consistently been shown to inhibit IGF-induced cell growth in vitro, similarly resulted in reduced growth in mice (30). Likewise, targeted deletion of IGFBP-2 in mice resulted in increase liver size but reduced spleen size (8).

Unlike the IGFBP-2 knockout mice, knockdown of IGFBP-2 in zebrafish embryos did not alter the levels of other IGFBPs, at least not detectably at the mRNA level; neither were changes observed in IGF-II mRNA levels. The IGF-I mRNA levels, however, were reduced in morphant embryos. At present, it is unclear whether the reductions in IGF-I mRNA expression are the direct result of reduced IGFBP-2 protein or represent a secondary defect of disrupted development and/or metabolism. It is possible that the reductions in IGF-I mRNA expression could be secondary to the observed cardiovascular dysfunction. It is well established in both mammals and lower vertebrates that IGF-I gene expression is influenced by nutritional status, during both fetal and postnatal stages (31, 32, 33, 34). Because one of the primary functions of the circulatory system during early development is to distribute nutritional resources derived from the yolk, the reduced circulatory function of IGFBP-2 knockdown embryos likely results in reduced distribution of nutritional resources to the growing embryo. Further studies are needed to distinguish between the proximate and ultimate causes of altered IGF-I mRNA expression after IGFBP-2 knockdown.

The development of brain edema, as observed in morphant embryos, is indicative of disruptions to the microvascular interface (choroid plexus) between the general circulation and the cerebral spinal fluid. The choroid plexus is a site of abundant IGFBP-2 expression in mammals (27, 35), and IGFBP-2 protein is found in abundance in rat cerebral spinal fluid (35). In this study, we detected strong expression of IGFBP-2 in brain boundary regions closely associated with cranial vascular tracts. We furthermore demonstrated, in flk1:GFP embryos, that angiogenic sprouting of secondary blood vessels between the primordial hindbrain channel and the basilar artery (16) was visibly disrupted in IGFBP-2 knockdown embryos. Our observations indicating malfunction of the choroid plexus after knockdown of IGFBP-2 are consistent with the reported expression patterns of IGFBP-2 in mammals and suggest that IGFBP-2 may be specifically required for early development of cranial microvascular structures.

The reductions in blood cell density observed in our study were temporally coincident with the onset of primary blood circulation. Before the onset of circulation, we did not detect any differences in hematopoietic transcription factor expression between knockdown and control-injected embryos. These data suggest that IGFBP-2 is probably not required for hematopoietic differentiation but may be involved in the survival of blood cells after the onset of circulation. We also observed a reduction in the heart rate of IGFBP-2 knockdown embryos. For two reasons, we suspect this to be a secondary defect resulting from the failure to develop a functional circulatory system. First, we did not detect IGFBP-2 expression in cardiac tissues during development; second, cardiac function in morphant embryos progressively declined as development proceeded, which is consistent with the progressive angiogenic defects.

Our experiments with flk1:GFP transgenic embryos provide novel in vivo evidence that IGFBP-2 is required for vascular development in zebrafish embryos. Whereas primary vessels (e.g. dorsal aorta, posterior cardinal vein) develop in the IGFBP-2 knockdown embryos, we observed distinct disruptions to angiogenic sprouting of secondary blood vessels. These defects were most evident in the lens and the brain, regions that exhibit high levels of IGFBP-2 mRNA expression during embryogenesis. Collectively, our findings in the zebrafish embryo contribute to an increasing body of evidence, indicating the importance of IGF signaling for vascular development in vertebrates. For example, IGF-I was shown to be necessary for normal vascularization of the human retina (36), whereas overexpression of IGF-I in mice ocular tissues recapitulated vascular defects associated with diabetes-like eye disease (37). In addition, IGF-I was shown to be required to stimulate blood vessel growth and remodeling in the rat brain under various metabolic circumstances (38).

Whereas cultured mammalian vascular endothelial cells have previously been shown to secrete IGFBPs (39), our preliminary colocalization experiments (data not shown) indicated that IGFBP-2 mRNA in the brain boundary regions did not directly colocalize with vascular endothelial cells, suggesting that that cells adjacent to vascular tissues, but not vascular endothelial cells per se, are the primary source of IGFBP-2 in zebrafish embryos. These findings are suggestive of a paracrine function for IGFBP-2 during angiogenic development.

In summary, we have shown that IGFBP-2 mRNA is expressed in temporally and spatially specific patterns during zebrafish embryonic development and that targeted knockdown of IGFBP-2 results in reduced embryo growth and distinct disruptions to embryonic vascular development. The defects in vascular development are most severe in regions associated with high levels of IGFBP-2 mRNA expression, suggesting a paracrine function for IGFBP-2. To our knowledge, this study is the first to provide in vivo evidence for the requirement of an IGFBP in vertebrate vascular development. In vitro, zebrafish IGFBP-2 binds to IGFs and was shown to inhibit IGF-induced cell proliferation (9). Likewise, overexpression of IGFBP-2 in zebrafish embryos inhibited IGF-stimulated somatic growth (40). It is therefore possible that IGFBP-2 affects embryonic vascular development in the zebrafish through its interaction with IGFs. Future studies will focus on the mechanisms of IGFBP-2 action and how IGFBP-2 works together with IGFs and/or other molecules to regulate vascular development.


    MATERIALS AND METHODS
 TOP
 ABSTRACT
 INTRODUCTION
 RESULTS
 DISCUSSION
 MATERIALS AND METHODS
 REFERENCES
 
Animals and Reagents
Adult wild-type zebrafish were purchased from a local supplier (University Aquarium, Ann Arbor, MI), maintained at 28 C in recirculated, reconditioned deionized water (conductivity 600 µS, pH 7.2) on a 14-h light, 10-h dark photoperiod and fed twice daily. Embryos were generated from natural crosses, reared in embryo medium (41), and staged as previously described (17). To inhibit embryo pigmentation, embryo medium was supplemented with 0.003% (wt/vol) 2-phenylthiourea beginning at 10 hpf. All experiments were conducted in accordance with guidelines as established by the University Committee on the Use and Care of Animals at the University of Michigan.

Standard chemicals and reagents were purchased from Fisher (Pittsburgh, PA) unless otherwise specified. RNA polymerase enzymes and ribonuclease-free deoxyribonuclease were purchased from Promega (Madison, WI). Restriction endonucleases were purchased from New England BioLabs (Beverly, MA). The Eppendorf MasterTaq Kit (Brinkmann, Westbury, NY) was used for all PCRs. Superscript II reverse transcriptase and oligonucleotide primers (Table 2Go) were purchased from Invitrogen Life Technologies, Inc. (Carlsbad, CA). MOs (Table 1Go) were purchased from Gene Tools, LLC (Philomath, OR).


View this table:
[in this window]
[in a new window]
 
Table 2. Oligonucleotide Primers Used in this Study

 
RT-PCR
Total RNA was purified from zebrafish embryos using Trizol reagent (Sigma, St. Louis, MO), digested with and ribonuclease-free deoxyribonuclease to remove contaminating genomic DNA. Purified RNA (500 ng) was reverse-transcribed to single strand cDNA using SuperScript II reverse transcriptase reagents according to the supplier’s instructions.

To detect IGFBP-2 mRNA expression in pregastrula embryos (0–10 hpf), we used an oligonucleotide primer pair (BP2-F1, BP2-R1; Table 2Go) designed to amplify a 426-bp fragment of the IGFBP-2 cDNA. A denaturing step (94 C for 5 min) was followed by 35 cycles in the following conditions: denaturation (94 C for 1 min), annealing (58 C for 1 min), and extension (72 C for 1 min), in an Eppendorf Mastercycler gradient thermocycler. To determine whether knockdown of IGFBP-2 alters the expression of other components of the IGF system, total RNA was purified from pools of control and IGFBP-2 morphant embryos (n = 20 embryos for each) at 48 hpf, and reverse-transcribed to cDNA as described above. Target genes were PCR-amplified using specific primers (Table 2Go) and examined after an appropriate number of cycles, ensuring amplification was terminated during the exponential phase; this was empirically determined for each target gene. PCR products were size-fractionated in 1% agarose gels, stained with ethidium bromide, and measured densitometrically using National Institutes of Health Image software (NIH, Bethesda, MD). The density of PCR products in control-injected and morphant embryos were directly compared in parallel reactions, using odc as an internal reference standard.

Whole Mount in Situ Hybridization
An 830-bp DNA fragment encoding the full-length zebrafish IGFBP-2 and its complete 3'-untranslated region (UTR) was subcloned into the pCS2+ vector (a gift from Dr. V. Prince, University of Chicago, Chicago, IL) using Xho1 and BamH1 restriction sites. Plasmid DNA for zebrafish gata1, scl, and Pax2.1 was provided by Drs. Susan Lyons and Pamela Raymond (University of Michigan). Purified plasmid DNA was linearized by restriction enzyme digestion to generate template for riboprobe synthesis. Digoxigenin-labeled riboprobes were synthesized by in vitro transcription as previously described (11). Whole-mount in situ hybridizations were performed on fixed embryos as previously described (11). Images were captured with a digital camera (Nikon COOLPIX995) mounted to a dissecting stereomicroscope, or with a Nikon DC50NN camera mounted to a Nikon Eclipse E600 microscope equipped with Nomarski optics (Melville, NY).

For cryosectioning analysis, embryos were refixed in paraformaldehyde as described, washed in PBS containing 0.1% Tween 20 (PBS-T), permeated with 15% sucrose in PBS-T, and embedded in OCT medium. OCT-embedded samples were frozen at –20 C and sectioned (10 µm) onto charged microscope slides (SuperFrost+) using a Leica CM3050 S cryostat (Solms, Germany). Embedding medium was removed by washing in room temperature PBS-T, and sections were examined with Nomarski optics.

MOs
Two MOs targeted against zebrafish IGFBP-2 were designed according to criteria provided by the commercial supplier (Gene Tools, LLC.): MO1 targeted nucleotides –45 to –20, and MO2 targeted nucleotides –26 to –2 (Table 1Go). A control MO (CTRL), composed of the inverted sequence of MO2, was used as a control for nonspecific effects of MO injection. Stock MO solutions [3 mM in Danieau buffer: 58 mM NaCl, 0.7 mM KCl, 0.4 mM MgSO4, 0.6 mM Ca(NO3)2, 5 mM HEPES (pH 7.6)] were diluted to working strength concentrations in Danieau buffer containing 0.25% phenol red.

Confirmation of MO Specificity
A 984-bp fragment of the zebrafish IGFBP-2 cDNA corresponding to the complete 5'-UTR region (including the MO target regions), the complete coding region, and a portion of the 3'-UTR region was generated by RT-PCR using designed primers (BP2MO-F1, BP2MO-R2; Table 2Go). The amplified cDNA product was subcloned into the pCR2.1-TOPO vector (Invitrogen Life Technologies). Plasmids with an insert in the sense direction were identified by restriction digestion analysis, and sequence accuracy was confirmed by automated sequencing. A 922-bp fragment of the subcloned insert (containing the MO target regions) was removed by digestion with BamH1 and Xho1, gel-purified (QIAQuick gel extraction kit), and subcloned into the pEGFP-N1 plasmid (CLONTECH, Palo Alto, CA) using Xho1 and BamH1 restriction sites. Expression of this plasmid insert (driven by the cytomegalovirus promoter) was predicted to yield a fusion protein of 513 amino acids (57.4 kDa), consisting of truncated IGFBP-2 (amino acids 1–268) fused to GFP at the C terminus (BP2:GFP).

Microinjection
MO or plasmid DNA solutions were microinjected into embryos at the 1–2 cell stage using drawn glass microcapillary pipettes attached to a micromanipulator. Injection was driven by compressed N2, under the control of a PV830 Pneumatic PicoPump (World Precision Instruments, Sarasota, FL). Microinjection volumes were estimated at 1 nl/embryo, based upon calibrations using known quantities of solution.

In preliminary experiments, control and antisense MOs were injected at 1.2, 2.5, 5.0, and 10 ng per embryo (final MO concentrations 0.12 –1.0 µM, assuming an oocyte volume of 1 µl); a nominal concentration of 2.5 ng MO per embryo yielded consistent, reproducible effects with both antisense MOs, whereas an equivalent amount of control MO (CTRL) yielded embryos indistinguishable from wild-type embryos. A nominal concentration of 2.5 ng MO/embryo was thus chosen for the majority of MO injection experiments.

Growth and Development
To measure embryo growth, embryos were anesthetized in a dilute solution of tricaine methanesulfonate, mounted in low-melting point agarose in a plastic tissue culture plate, and photographed under a dissection scope with a digital camera. The number of somite pairs/embryo was used as an indicator of developmental rate up to 24 hpf. Ear-tail length was measured in 56-hpf embryos to determine linear body growth in the hatching period.

Animated Images
To visualized blood flow in real-time, selected body regions were photomicrographed as sequential tagged-image files with a Nikon DC50NN camera mounted to a Nikon Eclipse E600 microscope. Images were captured using Scion Image software (Beta 4.0.2, Scion Corp., Frederick, MD), and converted to audio video interleave (.avi) format using ImageJ software (NIH).

Hemoglobin Staining
Erythrocytes were visualized by staining live embryos with o-dianisidine (Sigma), as previously described (19). Embryos were then fixed for 1 h in paraformaldehyde, washed in PBS-T, and digitally photographed as described above.

Heart Rate
Microinjected embryos at the desired stages were immobilized in low-melting point agarose, and the number of heart contractions in a 30-sec interval was determined under a dissecting microscope.

Embryonic Vascular Development
To visualize and quantify developing vascular structures, we used a line of transgenic zebrafish (flk1:GFP) with stable integration of a reporter construct (GFP) fused to the promoter region of the vascular endothelial growth factor receptor (flk1; Chan, S. J., and D. Stainier, personal communication). Transgenic embryos were generously provided by Dr. Didier Stainier (University of California at San Francisco), in liaison with Drs. John Kuwada and Qin Li (University of Michigan).

Data Analyses
Data are shown as means ± SEM. Differences in somite number, body length, heart rate, and cranial vessel number between morphant and control-injected embryos were statistically compared using an unpaired Student’s t test, after ensuring homogeneity of variances between groups. For semiquantitative RT-PCR, relative band densities were compared between morphant and control-injected groups using one-way ANOVA. Statistical significance was accepted when P < 0.05.


    ACKNOWLEDGMENTS
 
The authors thank Drs. D. Stainier and Wiebke Herzog, University of California at San Francisco, for generously providing the flk1:GFP zebrafish, in liaison with Drs. Q. Li and J. Kuwada; Drs. S. Lyons, V. Prince, and P. Raymond for providing reagents; and Shingo Kajimura for reading and commenting on this manuscript.


    FOOTNOTES
 
Current address for A.W.W.: Vincent Center for Reproductive Biology, Massachusetts General Hospital/Harvard Medical School, Boston, Massachusetts 02114.

This work was funded in part by National Science Foundation (NSF) Grant IBN 0110864 (to C.D.). A.W.W. was supported by a postdoctoral fellowship from the Natural Sciences and Engineering Research Council (NSERC) of Canada and by NSF Grant IBN 0110864.

First Published Online December 23, 2004

Abbreviations: GFP, Green fluorescent protein; hpf, hours post fertilization; IGFBP, IGF binding protein; MOs, morpholino-modified antisense oligonucleotides; odc, ornithine decarboxylase; PHBC, primordial hindbrain channel; scl, stem cell leukemia; UTR, untranslated region.

Received for publication October 1, 2004. Accepted for publication December 13, 2004.


    REFERENCES
 TOP
 ABSTRACT
 INTRODUCTION
 RESULTS
 DISCUSSION
 MATERIALS AND METHODS
 REFERENCES
 

  1. Clemmons DR 2001 Use of mutagenesis to probe IGF-binding protein structure/function relationships. Endocr Rev 22:800–817[Abstract/Free Full Text]
  2. Firth SM, Baxter RC 2002 Cellular actions of the insulin-like growth factor binding proteins. Endocr Rev 23:824–854[Abstract/Free Full Text]
  3. Pintar JE, Cerro JA, Wood TL 1996 Genetic approaches to the function of insulin-like growth factor-binding proteins during rodent development. Horm Res 45:172–177[Medline]
  4. Duan C 2002 Specifying the cellular responses to IGF signals: roles of IGF-binding proteins. J Endocrinol 175:41–54[Abstract/Free Full Text]
  5. Guler HP, Zapf J, Schmid C, Froesch ER 1989 Insulin-like growth factors I and II in healthy man. Estimations of half-lives and production rates. Acta Endocrinol (Copenh) 121:753–758[Medline]
  6. van Kleffens M, Groffen CAH, Dits NFJ, Lindenbergh-Kortleve DJ, Schuller AGP, Bradshaw SL, Pintar JE, Zwarthoff EC, Drop SLS, van Neck JW 1999 Generation of antisera to mouse insulin-like growth factor binding proteins (IGFBP)-1 to-6: Comparison of IGFBP protein and messenger ribonucleic acid localization in the mouse embryo. Endocrinology 140:5944–5952[Abstract/Free Full Text]
  7. Han VKM, Matsell DG Delhanty PJD 1996 IGF-binding protein mRNAs in the human fetus: tissue and cellular distribution of developmental expression. Horm Res 45:160–166[Medline]
  8. Wood TL, Rogler LE, Czick ME, Schuller AG, Pintar JE 2000 Selective alterations in organ sizes in mice with a targeted disruption of the insulin-like growth factor binding protein-2 gene. Mol Endocrinol 14:1472–1482[Abstract/Free Full Text]
  9. Vascotto SG, Beckham Y, Kelly GM 1997 The zebrafish’s swim to fame as an experimental model in biology. Biochem Cell Biol 75:479–485[CrossRef][Medline]
  10. Ekker SC, Larson JD 2001 Morphant technology in model developmental systems. Genesis 30:89–93[CrossRef][Medline]
  11. Maures TJ, Duan C 2002 Structure, developmental expression, and physiological regulation of zebrafish IGF binding protein-1. Endocrinology 143:2722–2731[Abstract/Free Full Text]
  12. Maures T, Chan SJ, Xu B, Sun H, Ding J, Duan C 2002 Structural, biochemical, and expression analysis of two distinct insulin-like growth factor I receptors and their ligands in zebrafish. Endocrinology 143:1858–1871[Abstract/Free Full Text]
  13. Funkenstein B, Tsai W, Maures T, Duan C 2002 Ontogeny, tissue distribution, and hormonal regulation of insulin-like growth factor binding protein-2 (IGFBP-2) in a marine fish, Sparus aurata. Gen Comp Endocrinol 128:112–122[CrossRef][Medline]
  14. Duan C, Ding J, Li Q, Tsai W, Pozios K 1999 Insulin-like growth factor binding protein 2 is a growth inhibitory protein conserved in zebrafish. Proc Natl Acad Sci USA 96:15274–15279[Abstract/Free Full Text]
  15. Pozios KC, Ding J, Degger B, Upton Z, Duan C 2001 IGFs stimulate zebrafish cell proliferation by activating MAP kinase and PI3-kinase-signaling pathways. Am J Physiol 280:R1230–R1239
  16. Isogai S, Horiguchi M, Weinstein BM 2001 The vascular anatomy of the developing zebrafish: an atlas of embryonic and early larval development. Dev Biol 230:278–301[CrossRef][Medline]
  17. Kimmel CB, Ballard WH, Kimmel SR, Ullmann B, Schilling TF 1995 Stages of embryonic development of the zebrafish. Dev Dyn 203:253–310[Medline]
  18. Warren KS, Baker K, Fishman MC 2001 The slow mo mutation reduces pacemaker current and heart rate in adult zebrafish. Am J Physiol Heart Circ Physiol 281:H1711–H1719
  19. Detrich III HW, Kieran MW, Chan FY, Barone LM, Yee K, Rundstadler JA, Pratt S, Ransom D, Zon LI 1995 Intraembryonic hematopoietic cell migration during vertebrate development. Proc Natl Acad Sci USA 92:10713–10717[Abstract/Free Full Text]
  20. Parker LH, Schmidt M, Jin S-K, Gray AM, Beis D, Pham T, Frantz G, Palmieri S, Hillan K, Stainier DY, de Sauvage FJ, Ye W 004 The endothelial-cell-derived secreted factor EGFL7 regulates vascular tube formation. Nature 428:754–758
  21. Stainier DY, Fouquet B, Chen JN, Warren KS, Weinstein BM, Meiler SE, Mohideen MA, Neuhauss SC, Solnica-Krezel L, Schier AF, Zwartkruis F, Stemple DL, Malicki J, Driever W, Fishman MC 1996 Mutations affecting the formation and function of the cardiovascular system in the zebrafish embryo. Development 123:285–292[Abstract/Free Full Text]
  22. Cantrell SM, Lutz LH, Tillitt DE, Hannink M 1996 Embryotoxicity of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD): the embryonic vasculature is a physiological target for TCDD-induced DNA damage and apoptotic cell death in medaka (Orizias latipes). Toxicol Appl Pharmacol 141:23–34[CrossRef][Medline]
  23. Cantrell SM, Joy-Schlezinger J, Stegeman JJ, Tillitt DE, Hannink M 1998 Correlation of 2,3,7,8-tetrachlorodibenzo-p-dioxin-induced apoptotic cell death in the embryonic vasculature with embryotoxicity. Toxicol Appl Pharmacol 148:24–34[CrossRef][Medline]
  24. Dong W, Teraoka H, Kondo S, Hiraga T 2001 2,3,7,8-Tetrachlorodibenzo-p-dioxin induces apoptosis in the dorsal midbrain of zebrafish embryos by activation of arylhydrocarbon receptor. Neurosci Lett 303:169–172[CrossRef][Medline]
  25. Nakae J, Kido Y, Accili D 2001 Distinct and overlapping functions of insulin and IGF-1 receptors. Endocr Rev 22:818–835[Abstract/Free Full Text]
  26. Allan GJ, Zannoni A, McKinnell I, Otto WR, Holzenberger M, Flint DJ, Patel K 2003 Major components of the insulin-like growth factor axis are expressed early in chicken embryogenesis, with IGF binding protein (IGFBP)-5 expression subject to regulation by Sonic Hedgehog. Anat Embryol (Berl) 207:73–84[CrossRef][Medline]
  27. Delhanty PJ, Han VK 1993 The expression of insulin-like growth factor (IGF)-binding protein-2 and IGF-II genes in the tissues of the developing ovine fetus. Endocrinology 132:41–52[Abstract]
  28. van Kleffens M, Groffen C, Neck JW, Vermeij-Keers C, Drop SL 1999 mRNA and protein localization of the IGF system during mouse embryonic development in areas with apoptosis. Growth Horm IGF Res 9:195–204[CrossRef][Medline]
  29. Orlowski CC, Brown AL, Ooi GT, Yang YW, Tseng LY, Rechler MM 1990 Tissue, developmental, and metabolic regulation of messenger ribonucleic acid encoding a rat insulin-like growth factor-binding protein. Endocrinology 126:644–652[Abstract]
  30. Pintar JE, Hoang B, Ning Y, Schuller A, Single and multiple knockouts of the IGFBPs. Program of the 83rd Annual Meeting of The Endocrine Society, Denver, CO, 2001, p 44 (Abstract S33-1)
  31. Straus DS, Ooi GT, Orlowski CC, Rechler MM 1991 Expression of the genes for insulin-like growth factor-1 (IGF-1), IGF-II, and IGF-binding proteins-1 and -2 in fetal rat under conditions of intrauterine growth retardation caused by maternal fasting. Endocrinology 128:518–525[Abstract]
  32. Duan C, Plisetskaya EM 1993 Nutritional regulation of insulin-like growth factor-1 mRNA expression in salmon tissues. J Endocrinol 139:243–252[Abstract]
  33. Thissen JP, Ketelslegers JM, Underwood LE 1994 Nutritional regulation of the insulin-like growth factors. Endocr Rev 15:80–101[Abstract]
  34. Kita K, Tomas FM, Owens PC, Knowles SE, Forbes BE, Upton Z, Hughes R, Ballard FJ 1996 Influence of nutrition on hepatic IGF-1 mRNA levels and plasma concentrations of IGF-I and IGF-II in meat-type chickens. J Endocrinol 149:181–190[Abstract]
  35. Walter HJ, Berry M, Hill DJ, Cwyfan-Hughes S, Holly JM, Logan A 1999 Distinct sites of insulin-like growth factor (IGF)-II expression and localization in lesioned rat brain: possible roles of IGF binding proteins (IGFBPs) in the mediation of IGF-II activity. Endocrinology 140:520–532[Abstract/Free Full Text]
  36. Hellstrom A, Carlsson B, Niklasson A, Segnestam K, Boguszewski M, de Lacerda L, Savage M, Svensson E, Smith L, Weinberger D, Albertsson Wikland K, Laron Z 2002 IGF-1 is critical for normal vascularization of the human retina. J Clin Endocrinol Metab 87:3413–3416[Abstract/Free Full Text]
  37. Ruberte J, Ayuso E, Navarro M, Carretero A, Nacher V, Haurigot V, George M, Llombart C, Casellas A, Costa C, Bosch A, Bosch F 2004 Increased ocular levels of IGF-1 in transgenic mice lead to diabetes-like eye disease. J Clin Invest 113:1149–1157[Abstract/Free Full Text]
  38. Lopez-Lopez C, LeRoith D, Torres-Aleman I 2004 Insulin-like growth factor I is required for vessel remodeling in the adult brain. Proc Natl Acad Sci USA 101:9833–9838[Abstract/Free Full Text]
  39. Bar RS, Booth BA, Boes M, Dake BL 1989 Insulin-like growth factor-binding proteins from vascular endothelial cells: purification, characterization, and intrinsic biological activities. Endocrinology 125:1910–1920[Abstract]
  40. Duan C 2002 Regulation of insulin-like growth factor (IGF) actions by IGF binding proteins in zebrafish. Fish Sci 68:765–768
  41. Westerfield M 1995 The zebrafish book. Eugene, OR: University of Oregon Press